Pricing Availability Delivery Time Qty
Cat.No. 2967 - Phenserine | C20H23N3O2 | CAS No. 101246-66-6
Description: Cholinesterase inhibitor
Chemical Name: (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol 5-(N-phenylcarbamate)
Purity: ≥98% (HPLC)
Citations (1)

Biological Activity

Physostigmine analog that inhibits acetylcholinesterase. Inhibits production of amyloid precursor protein (APP) and Aβ. Improves morris water maze performance of scopolamine-treated rats.

Technical Data

M. Wt 337.42
Formula C20H23N3O2
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 101246-66-6
PubChem ID 192706
Smiles O=C(OC2=CC=C(N(C)[C@]4([H])[C@](C)3CCN4C)C3=C2)NC1=CC=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 3.37 10
ethanol 8.44 25

Preparing Stock Solutions

The following data is based on the product molecular weight 337.42. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.96 mL 14.82 mL 29.64 mL
5 mM 0.59 mL 2.96 mL 5.93 mL
10 mM 0.3 mL 1.48 mL 2.96 mL
50 mM 0.06 mL 0.3 mL 0.59 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet


References are publications that support the products' biological activity.

Janas et al (2005) The cholinesterase inhibitor, phenserine, improves morris water maze performance of scopolamine-treated rats. Life Sci. 76 1073 PMID: 15620572

Utsuki et al (2006) Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-β peptide. J.Pharmacol.Exp.Ther. 318 855 PMID: 16690718

Klein (2007) Phenserine. Expert Opin.Investig.Drugs 16 1087 PMID: 17594192

If you know of a relevant reference for Phenserine, please let us know.

View Related Products by Product Action

View all Cholinesterase Inhibitors

Keywords: Phenserine, supplier, Cholinesterase, inhibitors, inhibits, AChE, Acetylcholinesterase, Esterases, Acetylcholine, Nicotinic, Receptors, nAChR, Muscarinic, Cholinesterases, Non-selective, Muscarinics, Cholinesterases, Tocris Bioscience

1 Citation for Phenserine

Citations are publications that use Tocris products. Selected citations for Phenserine include:

Elgueta et al (2015) Acetylcholine induces GABA release onto rod bipolar cells through heteromeric nicotinic receptors expressed in A17 amacrine cells. Sci Rep 9 6 PMID: 25709566

Do you know of a great paper that uses Phenserine from Tocris? If so please let us know.

Reviews for Phenserine

There are currently no reviews for this product. Be the first to review Phenserine and earn rewards!

Have you used Phenserine?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.